Blueprint Medicines Corporation
BPMC
$87.11
-$2.90-3.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -67.09M | -128.05M | -205.49M | -288.29M | -506.98M |
| Total Depreciation and Amortization | 16.29M | 13.82M | 12.83M | 12.79M | 11.67M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.10M | -83.78M | -83.70M | -81.99M | 99.60M |
| Change in Net Operating Assets | -64.69M | -44.14M | -56.64M | -57.91M | -41.13M |
| Cash from Operations | -192.59M | -242.15M | -333.00M | -415.40M | -436.85M |
| Capital Expenditure | -4.63M | -8.37M | -14.60M | -14.58M | -16.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.87M | 5.93M | -27.38M | 192.96M | 290.10M |
| Cash from Investing | -47.50M | -2.44M | -41.98M | 178.38M | 274.04M |
| Total Debt Issued | 146.97M | 146.94M | 244.91M | 97.93M | 97.93M |
| Total Debt Repaid | -541.00K | -585.00K | -585.00K | -413.00K | -44.00K |
| Issuance of Common Stock | 126.68M | 132.53M | 114.58M | 88.67M | 21.34M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 273.11M | 278.88M | 358.90M | 186.19M | 119.23M |
| Foreign Exchange rate Adjustments | -909.00K | 902.00K | -230.00K | -140.00K | 202.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.12M | 35.19M | -16.30M | -50.97M | -43.38M |
